Merck & Co. Reports the Resubmission of sBLA to the US FDA for Keytruda (pembrolizumab) Six-Week Dosing Schedule

 Merck & Co. Reports the Resubmission of sBLA to the US FDA for Keytruda (pembrolizumab) Six-Week Dosing Schedule

Merck & Co. Reports the Resubmission of sBLA to the US FDA for Keytruda (pembrolizumab) Six-Week Dosing Schedule

Shots:

  • The company resubmits the sBLA to the FDA for updating the dosing frequency for Keytruda, to include a 400mg dose infused over 30mis q6w, in addition to the currently approved dose of 200mg q3w
  • Merck has filed the resubmission addressing the Complete Response Letter issued in Febr’2020 and filed sBLA across all indications of Keytruda, including monothx. and combination therapy
  • Keytruda is a mAb blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thus activating T lymphocytes affecting both tumor cells and healthy cells

Click here ­to­ read full press release/ article | Ref: Merck | Image: Merck

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post